Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

1 Obe-cel is a chimeric antigen receptor (CAR) T-cell therapy that is the first approved by the FDA without a requirement for ...

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

To date, the Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapy products targeting CD19 and BCMA for B-cell lymphomas, leukemias and multiple myeloma, ...

The first UK patients have received an innovative immunotherapy to treat the most serious form of lupus, as part of a ...

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will ...

MB-109 is Mustang's regimen that combines MB-101, a chimeric antigen receptor (CAR)-T-cell therapy targeting interleukin 13 ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

A woman in Manchester is the first person in the UK to receive an innovative treatment for the most serious form of lupus – an autoimmune condition which can ...

Mustang Bio, Inc. (NASDAQ: MBIO) disclosed in a recent 8-K filing with the Securities and Exchange Commission that the company has scheduled its 2024 annual meeting of stockholders for December 26, ...